{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:43:39Z","timestamp":1793119419061,"version":"4.5.0"},"reference-count":28,"publisher":"American Society of Hematology","issue":"1","license":[{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,9]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>In situ vaccination (ISV) triggers an immune response to tumor-associated antigens at 1 tumor site, which can then tackle the disease throughout the body. Here, we report clinical and biological results of a phase 1\/2 ISV trial in patients with low-grade lymphoma, combining an intratumoral toll-like receptor 9 (TLR9) agonist with local low-dose radiation and ibrutinib (an inhibitor of B- and T-cell kinases). Adverse events were predominately low grade. The overall response rate was 50%, including 1 complete response. All patients experienced tumor reduction at distant sites. Single-cell analyses of serial fine needle aspirates from injected and uninjected tumors revealed correlates of clinical response, such as lower CD47 and higher major histocompatibility complex class II expression on tumor cells, enhanced T-cell and natural killer cell effector function, and reduced immune suppression from transforming growth factor \u03b2 and inhibitory T regulatory 1 cells. Although changes at the local injected site were more pronounced, changes at distant uninjected sites were more often associated with clinical responses. Functional immune response assays and tracking of T-cell receptor sequences provided evidence of treatment-induced tumor-specific T-cell responses. Induction of immune effectors and reversal of negative regulators were both important in producing clinically meaningful tumor responses. The trial was registered at www.clinicaltrials.gov as #NCT02927964.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011589","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T20:14:48Z","timestamp":1699474488000},"page":"130-142","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["A clinical trial of therapeutic vaccination in lymphoma with serial tumor sampling and single-cell analysis"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0694-3512","authenticated-orcid":false,"given":"Tanaya","family":"Shree","sequence":"first","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford University, CA"},{"name":"2Division of Hematology & Medical Oncology, Department of Medicine, Oregon Health and Sciences University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Haebe","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford University, CA"},{"name":"3Medical Department III, Ludwig Maximilian University Hospital, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra K.","family":"Czerwinski","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford University, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Eckhert","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford University, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9150-1182","authenticated-orcid":false,"given":"Grady","family":"Day","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford University, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2100-0013","authenticated-orcid":false,"given":"Anuja","family":"Sathe","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford University, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Grimes","sequence":"additional","affiliation":[{"name":"4Stanford Genome Technology Center, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Frank","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford University, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren S.","family":"Maeda","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford University, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5153-5625","authenticated-orcid":false,"given":"Ash A.","family":"Alizadeh","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford University, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana","family":"Advani","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford University, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0125-0194","authenticated-orcid":false,"given":"Richard T.","family":"Hoppe","sequence":"additional","affiliation":[{"name":"5Department of Radiation Oncology, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Long","sequence":"additional","affiliation":[{"name":"6Department of Pathology, Stanford University School of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brock","family":"Martin","sequence":"additional","affiliation":[{"name":"6Department of Pathology, Stanford University School of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Ozawa","sequence":"additional","affiliation":[{"name":"6Department of Pathology, Stanford University School of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9061-7351","authenticated-orcid":false,"given":"Michael S.","family":"Khodadoust","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford University, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanlee P.","family":"Ji","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford University, CA"},{"name":"4Stanford Genome Technology Center, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Levy","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford University, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,12,29]]},"reference":[{"issue":"8","key":"2024010914591404400_bib1","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1080\/14737140.2021.1915136","article-title":"Development of CpG oligodeoxynucleotide TLR9 agonists in anti-cancer therapy","volume":"21","author":"Jin","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"key":"2024010914591404400_bib2","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1200\/JCO.2010.28.9793","article-title":"In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I\/II study","volume":"28","author":"Brody","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2024010914591404400_bib3","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1158\/2159-8290.CD-18-0743","article-title":"In situ vaccination with a TLR9 agonist and local low-dose radiation induces systemic responses in untreated indolent lymphoma","volume":"8","author":"Frank","year":"2018","journal-title":"Cancer Discov"},{"issue":"13","key":"2024010914591404400_bib4","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood-2014-08-593137","article-title":"Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma","volume":"125","author":"Sagiv-Barfi","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2024010914591404400_bib5","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.3109\/10428194.2013.777837","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)","volume":"54","author":"Burger","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"2024010914591404400_bib6","article-title":"Ibrutinib KINOMEscan","author":"Wang","year":"2015","journal-title":"LINCS"},{"issue":"15","key":"2024010914591404400_bib7","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2024010914591404400_bib8","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3390\/ijms21010068","article-title":"Harnessing the effects of BTKi on T-cells for effective immunotherapy against CLL","volume":"21","author":"Mhibik","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2024010914591404400_bib9","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/cncy.22531","article-title":"Serial FNA allows direct sampling of malignant and infiltrating immune cells in patients with B-cell lymphoma receiving immunotherapy","volume":"130","author":"Mooney","year":"2022","journal-title":"Cancer Cytopathol"},{"issue":"11","key":"2024010914591404400_bib10","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1093\/annonc\/mdy423","article-title":"Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)","volume":"29","author":"Marabelle","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"2024010914591404400_bib11","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","article-title":"Comprehensive integration of single-cell data","volume":"177","author":"Stuart","year":"2019","journal-title":"Cell"},{"key":"2024010914591404400_bib12","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3389\/fimmu.2017.00304","article-title":"Type I interferons and natural killer cell regulation in cancer","volume":"8","author":"M\u00fcller","year":"2017","journal-title":"Front Immunol"},{"issue":"2","key":"2024010914591404400_bib13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cytogfr.2014.11.003","article-title":"NK cells and interferons","volume":"26","author":"Paolini","year":"2015","journal-title":"Cytokine Growth Factor Rev"},{"issue":"4","key":"2024010914591404400_bib14","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth factor-\u03b2 signaling in immunity and cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"issue":"6","key":"2024010914591404400_bib15","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.immuni.2018.12.001","article-title":"The biology of T regulatory type 1 cells and their therapeutic application in immune-mediated diseases","volume":"49","author":"Roncarolo","year":"2018","journal-title":"Immunity"},{"key":"2024010914591404400_bib16","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/blood-2017-09-804641","article-title":"Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial","volume":"131","author":"Bartlett","year":"2018","journal-title":"Blood"},{"issue":"23","key":"2024010914591404400_bib17","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.2017.76.8853","article-title":"Ibrutinib as treatment for patients with relapsed\/refractory follicular lymphoma: results from the open-label, multicenter, phase II DAWN study","volume":"36","author":"Gopal","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"7647","key":"2024010914591404400_bib18","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nature21433","article-title":"Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens","volume":"543","author":"Khodadoust","year":"2017","journal-title":"Nature"},{"issue":"8","key":"2024010914591404400_bib19","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood-2018-06-845156","article-title":"B-cell lymphomas present immunoglobulin neoantigens","volume":"133","author":"Khodadoust","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2024010914591404400_bib20","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/s41591-019-0410-x","article-title":"Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination","volume":"25","author":"Hammerich","year":"2019","journal-title":"Nat Med"},{"issue":"24","key":"2024010914591404400_bib21","doi-asserted-by":"crossref","first-page":"9531","DOI":"10.3390\/ijms21249531","article-title":"CD37 in B-cell derived tumors\u2014more than just a docking point for monoclonal antibodies","volume":"21","author":"Bobrowicz","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"12","key":"2024010914591404400_bib22","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1200\/JCO.18.02018","article-title":"First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers","volume":"37","author":"Sikic","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"2024010914591404400_bib23","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2024010914591404400_bib24","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0962-8924(00)01906-1","article-title":"Integrin-associated protein (CD47) and its ligands","volume":"11","author":"Brown","year":"2001","journal-title":"Trends Cell Biol"},{"issue":"250","key":"2024010914591404400_bib25","doi-asserted-by":"crossref","first-page":"ra82","DOI":"10.1126\/scisignal.2003113","article-title":"The tetraspanin CD37 orchestrates the \u03b14\u03b21 integrin\u2013Akt signaling axis and supports long-lived plasma cell survival","volume":"5","author":"van Spriel","year":"2012","journal-title":"Sci Signal"},{"issue":"6","key":"2024010914591404400_bib26","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.it.2010.04.001","article-title":"Macrophages as mediators of tumor immunosurveillance","volume":"31","author":"Jaiswal","year":"2010","journal-title":"Trends Immunol"},{"issue":"1","key":"2024010914591404400_bib27","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-020-00930-1","article-title":"Role of CD47 in hematological malignancies","volume":"13","author":"Eladl","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"issue":"5","key":"2024010914591404400_bib28","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1182\/blood.2019004753","article-title":"Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed\/refractory follicular lymphoma","volume":"137","author":"Armand","year":"2021","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/1\/130\/2180434\/blooda_adv-2023-011589-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/1\/130\/2180434\/blooda_adv-2023-011589-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T14:59:37Z","timestamp":1704812377000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/1\/130\/498657\/A-clinical-trial-of-therapeutic-vaccination-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,29]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011589","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,29]]}}}